Kurzfassung

This phase 3, two-armed, randomized, active comparator-controlled, open label, multicenter study will compare the efficacy and assess the safety of selinexor plus bortezomib (Velcade or generic equivalent) plus low-dose dexamethasone (SVd) versus bortezomib plus low dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple myeloma (MM) regimens.